WO2023073429 - METHODS OF USING ANTI-EGF ANTIBODIES TO AUGMENT THE ACTIVITY OF BRAF AND KRAS INHIBITORS
National phase entry:
Publication Number
WO/2023/073429
Publication Date
04.05.2023
International Application No.
PCT/IB2022/000655
International Filing Date
28.10.2022
Title **
[English]
METHODS OF USING ANTI-EGF ANTIBODIES TO AUGMENT THE ACTIVITY OF BRAF AND KRAS INHIBITORS
[French]
MÉTHODES D'UTILISATION D'ANTICORPS ANTI-EGF POUR AUGMENTER L'ACTIVITÉ D'INHIBITEURS DE BRAF ET DE KRAS
Applicants **
IN3BIO LTD.
D'HONDT, Erik
MOLINA-VILA, Miguel, Angel
Inventors
D'HONDT, Erik
MOLINA-VILA, Miguel, Angel
Priority Data
63/272,822
28.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2210 | |
| EPO | Filing, Examination, Granting | 9687 | |
| Japan | Filing, Examination, Granting | 2243 | |
| South Korea | Filing, Examination, Granting | 2139 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
22,219
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Embodiments of the present disclosure are directed to methods for treating and preventing disease conditions, such as cancer, particularly in those individuals who have developed a resistance to, or who are not responsive to, cancer therapies involving v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) or Kirsten rat sarcoma oncogene homolog (KRAS) inhibitors.[French]
Des modes de réalisation de la présente divulgation concernent des méthodes de traitement et de prévention d'états pathologiques, tels que le cancer, en particulier chez les individus qui ont développé une résistance à, ou qui ne sont pas sensibles aux cancérothérapies impliquant des inhibiteurs de l'homologue de l'oncogène BI viral du sarcome murin v-Raf (BRAF) ou des inhibiteurs de l'homologue de l'oncogène du sarcome de rat de Kirsten (KRAS).